NASDAQ:VRMLVermillion Stock Price, Forecast & News

Vermillion's stock was trading at $0.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VRML stock has increased by 346.4% and is now trading at $3.75. View which stocks have been most impacted by Coronavirus.

Vermillion is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Vermillion.

Vermillion, Inc. (NASDAQ:VRML) announced its quarterly earnings results on Thursday, March, 26th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business earned $1.31 million during the quarter. Vermillion had a negative net margin of 307.31% and a negative return on equity of 155.25%. View Vermillion's earnings history.

Media stories about VRML stock have trended very negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Vermillion earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutVermillion.

Vermillion saw a drop in short interest in April. As of April 30th, there was short interest totaling 2,200,000 shares, a drop of 18.2% from the April 15th total of 2,690,000 shares. Based on an average daily volume of 163,100 shares, the days-to-cover ratio is currently 13.5 days. Currently, 4.4% of the company's stock are sold short. View Vermillion's Current Options Chain.

Some companies that are related to Vermillion include Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Heska (HSKA), Meridian Bioscience (VIVO), Quotient (QTNT), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), ImmuCell (ICCC), GeneNews (GNWSF), Akers Biosciences (AKER) and Achieve Life Sciences (ACHV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vermillion investors own include CombiMatrix (CBMX), Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Idera Pharmaceuticals (IDRA), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), TrovaGene (TROV), Charter Communications (CHTR), Fluidigm (FLDM) and Magnachip Semiconductor (MX).

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

Vermillion's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Lincoln National Corp (0.20%), BlackRock Inc. (0.14%), Commonwealth Equity Services LLC (0.13%), Oxford Financial Group Ltd. (0.07%), Magnus Financial Group LLC (0.06%) and Trellus Management Company LLC (0.03%). Company insiders that own Vermillion stock include David Schreiber, Jack W Schuler, James T Lafrance, Robert Harry Beechey and Valerie Barber Palmieri. View institutional ownership trends for Vermillion.

VRML stock was sold by a variety of institutional investors in the last quarter, including Magnus Financial Group LLC, and Trellus Management Company LLC. View insider buying and selling activity for Vermillion.

VRML stock was acquired by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, Oxford Financial Group Ltd., Lincoln National Corp, Heritage Investors Management Corp, and BlackRock Inc.. Company insiders that have bought Vermillion stock in the last two years include Jack W Schuler, Robert Harry Beechey, and Valerie Barber Palmieri. View insider buying and selling activity for Vermillion.

Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRML stock can currently be purchased for approximately $3.75.

Vermillion has a market capitalization of $365.17 million and generates $4.54 million in revenue each year. Vermillion employs 43 workers across the globe.

The official website for Vermillion is www.vermillion.com.

Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]